about
Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar AffinitiesSmall-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1αTargeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α InteractionDiscovery of novel inhibitors disrupting HIF-1α/von Hippel-Lindau interaction through shape-based screening and cascade dockingPotent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibitionHypoxia-inducible factor activation protects the kidney from gentamicin-induced acute injury.Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complexRole of Hypoxia Inducible Factor-1α (HIF-1α) in Innate Defense against Uropathogenic Escherichia coli Infection.Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasisAffinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 InhibitorsSignaling hypoxia by hypoxia-inducible factor protein hydroxylases: a historical overview and future perspectivesHIF-prolyl hydroxylases and cardiovascular diseases.Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials.Erythropoiesis stimulating agents: approaches to modulate activity.Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications.Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex.Equine performance genes and the future of doping in horseracing.Emerging drugs for the treatment of kidney disease-induced anemia.Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863.Renal CD133(+)/CD73(+) progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition.What are the Considerations in Balancing Benefits and Risks in Iron Treatment?: How Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors May Change Iron Management in End-Stage Renal Disease.Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure-Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-Regulation of immunity and inflammation by hypoxia in immunological niches.Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.QSAR modeling and in silico design of small-molecule inhibitors targeting the interaction between E3 ligase VHL and HIF-1α.Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
P2860
Q27640584-95403532-2120-4DB5-8677-81598633FF51Q27674529-345D34D4-92B0-4F13-B04F-E6FB8F1E065DQ27677509-08A46058-5D40-4BFD-ACB3-14C9AA786FFEQ28817163-38AB5F5C-3371-4872-B17F-ECB0D5015242Q28822022-B20846D2-0BB9-46F3-9C38-0C39516CFE87Q34473806-9BBF1001-545F-4441-A55E-9D5F5533E440Q34505760-470CD1C1-CF56-4801-9AAF-8CE39F827574Q35152151-3CA4F24B-DA14-44E3-B5E9-00DAD7C750C4Q35557736-94562063-1991-466C-A158-E98FB47DBE96Q36327483-AA33B61C-4D03-4D0C-8F56-F0CEC5B84077Q36367302-A0B49EC0-5E4E-443E-ABC1-056EED0BB2B1Q37301035-A306243E-5955-4C7C-9C2A-B42BC05E13CDQ37994258-E052FE31-3FFF-4772-B7E8-91827C99DBDDQ38103912-6C0B29A3-AD1F-4DAB-9E7D-001F9BE19818Q38121067-7059197B-C20F-4A67-A5BC-CFF8D5078414Q38648760-C8F795D5-07A9-4D0A-947A-694648819E39Q38673650-4798BBFE-2930-4955-8ACF-678C6909DA99Q38738678-5C6DABEF-5321-417F-A906-64071080481FQ38930912-D2F4F178-07D8-463E-953D-BA2767016A8FQ39810440-699C55AB-9DD6-4F1D-AF2D-B6469F180FFBQ41762118-DF0BA8B0-05F4-44AD-AE48-7EB842274B7FQ46224147-53C61A4D-7F5C-4822-A132-3A9355745560Q47324161-6825B9F7-84B1-43C1-BE5E-510D36A20F32Q47708732-A866AC7D-1DEE-4294-BEDC-30FBC5EC9AADQ48140646-4EBB3BFA-6CC2-47AF-9E71-648E99336980Q49176400-5F6C5B37-4A86-4856-9D73-F3DC844FB3C2Q50901314-560EF72C-E90D-4CD6-B25B-AEC09BE000EBQ52683262-1560BA35-1F7B-4EDD-9A28-FAD8F39CB900Q53354414-AC42BBC1-A244-489B-9BF3-1BB135F6DBD2
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
HIF prolyl hydroxylase inhibitors for anemia
@ast
HIF prolyl hydroxylase inhibitors for anemia
@en
HIF prolyl hydroxylase inhibitors for anemia
@nl
type
label
HIF prolyl hydroxylase inhibitors for anemia
@ast
HIF prolyl hydroxylase inhibitors for anemia
@en
HIF prolyl hydroxylase inhibitors for anemia
@nl
prefLabel
HIF prolyl hydroxylase inhibitors for anemia
@ast
HIF prolyl hydroxylase inhibitors for anemia
@en
HIF prolyl hydroxylase inhibitors for anemia
@nl
P2860
P3181
P1476
HIF prolyl hydroxylase inhibitors for anemia
@en
P2093
Eugene Muchnik
Joshua Kaplan
P2860
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency
P304
P3181
P356
10.1517/13543784.2011.566861
P407
P577
2011-05-01T00:00:00Z